(Q37549946)

21 August 2017

1 reference

title

Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer (English)

1 reference

21 August 2017

1 reference

P F Mulders

1

1 reference

21 August 2017

J A Schalken

series ordinal

2

1 reference

21 August 2017

publication date

14 July 2009

1 reference

Prostate Cancer and Prostatic Diseases

21 August 2017

published in

1 reference

21 August 2017

volume

12

1 reference

21 August 2017

issue

3

1 reference

21 August 2017

page(s)

241-246

1 reference

Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.25

Surrogate end points in clinical trials: are we being misled?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.25

Surrogate endpoints in clinical trials: definition and operational criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.25

Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.25

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.25

Clinical trials in relapsed prostate cancer: defining the target

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.25

Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.25

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.25

Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.25

Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 tria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.25

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.25

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.25

Targeted therapy in prostate cancer--are we our own worst enemy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.25

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.25

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.25

Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.25

The hazards of intermediate endpoints

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.25

Assessing outcomes in prostate cancer clinical trials: a twenty-first century tower of Babel

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.25

The association between measures of progression and survival in castrate-metastatic prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.25

Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.25

Prostate cancer clinical trial end points: "RECIST"ing a step backwards.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.25

Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.25

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.25

Challenges to use of health-related quality of life for Food and Drug Administration approval of anticancer products.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.25

Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.25

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.25

Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.25

Circulating tumor cells predict survival in patients with metastatic prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.25

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.25

CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.25

Prostate cancer diagnosis in the new millennium: strengths and weaknesses of prostate-specific antigen and the discovery and clinical evaluation of prostate cancer gene 3 (PCA3).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.25

Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.25

Molecular pathology of prostate cancer: the key to identifying new biomarkers of disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.25

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.25

TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.25

31 March 2020

Identifiers

DOI

10.1038/PCAN.2009.25

1 reference

21 August 2017

1 reference